CCNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: We have shown that reduction of cyclin A2 in human chronic myelogenous leukaemia K562 cells using small interfering RNA significantly inhibits cell proliferation [20], further supporting the notion that cyclin A2 can serve as a novel therapeutic target.